aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE) announced on August 3, 2021, that it will report its second quarter 2021 financial results and provide a corporate update on August 10, 2021, after the market closes. A conference call and webcast are scheduled for the same day at 5:00 PM EDT. The company focuses on developing innovative medicines based on novel biological pathways, particularly their clinical-stage product candidate, ATYR1923, aimed at treating inflammatory lung diseases.

Positive

• Scheduled conference call on August 10 will provide vital financial updates.
• Focus on clinical-stage product candidate ATYR1923 could indicate future revenue potential.

Negative

• None.

Management to host conference call and webcast on August 10th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results and provide a corporate update after the market close on Tuesday, August 10, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

Conference Call and Webcast Details:
Tuesday, August 10th @ 5:00 pm EDT / 2:00 pm PDT
Domestic: 844-358-9116
International: 209-905-5951
Conference ID: 4692110
Webcast: http://investors.atyrpharma.com/events-and-webcasts

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

When is aTyr Pharma's next earnings report?

aTyr Pharma is scheduled to report its second quarter 2021 financial results on August 10, 2021.

What is the significance of ATYR1923 for aTyr Pharma?

ATYR1923 is a clinical-stage product candidate aimed at down-regulating immune engagement in inflammatory lung diseases, which is central to aTyr's development efforts.

How can I participate in the aTyr Pharma conference call?

You can participate in the conference call by calling 844-358-9116 for domestic or 209-905-5951 for international calls, using conference ID 4692110.